1. Home
  2. HTGC vs SRRK Comparison

HTGC vs SRRK Comparison

Compare HTGC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTGC
  • SRRK
  • Stock Information
  • Founded
  • HTGC 2003
  • SRRK 2012
  • Country
  • HTGC United States
  • SRRK United States
  • Employees
  • HTGC 100
  • SRRK N/A
  • Industry
  • HTGC Investment Managers
  • SRRK Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • HTGC Finance
  • SRRK Health Care
  • Exchange
  • HTGC Nasdaq
  • SRRK Nasdaq
  • Market Cap
  • HTGC 3.5B
  • SRRK 4.2B
  • IPO Year
  • HTGC 2005
  • SRRK 2018
  • Fundamental
  • Price
  • HTGC $20.97
  • SRRK $40.03
  • Analyst Decision
  • HTGC Buy
  • SRRK Strong Buy
  • Analyst Count
  • HTGC 8
  • SRRK 7
  • Target Price
  • HTGC $20.88
  • SRRK $40.43
  • AVG Volume (30 Days)
  • HTGC 813.2K
  • SRRK 1.0M
  • Earning Date
  • HTGC 02-13-2025
  • SRRK 03-18-2025
  • Dividend Yield
  • HTGC 9.13%
  • SRRK N/A
  • EPS Growth
  • HTGC 1.34
  • SRRK N/A
  • EPS
  • HTGC 2.01
  • SRRK N/A
  • Revenue
  • HTGC $494,410,000.00
  • SRRK N/A
  • Revenue This Year
  • HTGC $10.55
  • SRRK N/A
  • Revenue Next Year
  • HTGC $5.06
  • SRRK N/A
  • P/E Ratio
  • HTGC $10.43
  • SRRK N/A
  • Revenue Growth
  • HTGC 12.81
  • SRRK N/A
  • 52 Week Low
  • HTGC $16.95
  • SRRK $6.76
  • 52 Week High
  • HTGC $21.78
  • SRRK $46.98
  • Technical
  • Relative Strength Index (RSI)
  • HTGC 61.19
  • SRRK 42.91
  • Support Level
  • HTGC $20.65
  • SRRK $38.86
  • Resistance Level
  • HTGC $21.25
  • SRRK $43.94
  • Average True Range (ATR)
  • HTGC 0.27
  • SRRK 2.56
  • MACD
  • HTGC -0.00
  • SRRK -0.66
  • Stochastic Oscillator
  • HTGC 75.00
  • SRRK 14.35

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company engaged in providing senior secured loans to high-growth, venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. It invests majorly in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. The company lends to and invests in portfolio companies in various technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology.

About SRRK Scholar Rock Holding Corporation

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Share on Social Networks: